Resummation Methods at Finite Temperature: The Tadpole Way

We examine several resummation methods for computing higher order corrections to the finite temperature effective potential, in the context of a scalar $\phi^4$ theory. We show by explicit calculation to four loops that dressing the propagator, not the vertex, of the one-loop tadpole correctly counts ``daisy'' and ``super-daisy'' diagrams.Comment: 18 pages, LaTeX, CALT-68-1858, HUTP-93-A011, EFI-93-2

A comparative study of free oligosaccharides in the milk of domestic animals

This study was conducted to provide a comprehensive analysis of the oligosaccharides in the milk of a variety of important domestic animals including cow, goat, sheep, pig, horse, and dromedary camel. Using an analytical workflow which included ultra-performance hydrophilic interaction liquid chromatography with fluorescence detection (UPLC-HILIC-FLD) and coupling to a quadrupole time of flight (qTOF) mass spectrometer (MS), detailed oligosaccharide libraries were established. The partial or full characterization of the neutral/fucosylated, phosphorylated and sialylated structures was facilitated by sequencing with linkage- and sugar- specific exoglycosidases. Relative peak quantification of the 2-AB labelled oligosaccharides provided additional information. Milks from domestic animals contained a much larger variety of complex oligosaccharides than was previously assumed and thirteen of these structures were previously identified in human milk. The direct comparison of the oligosaccharide mixtures could contribute to a better understanding of possible differences in their biological effects and highlight the potential value of animal milks for commercial oligosaccharide extraction.Fil: Albrecht, Simone. National Institute for Bioprocessing, Research and Training. NIBRT GlycoScience Group; IrlandaFil: Lane, Jonathan A.. Teagasc Food Research Centre; IrlandaFil: Mariño, Karina Valeria. National Institute for Bioprocessing, Research and Training. NIBRT GlycoScience Group; Irlanda. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); ArgentinaFil: Al Busadah, Khalid A.. King Faisal University. Camel Research Center; Arabia SauditaFil: Carrington, Stephen D.. University College Dublin. Veterinary Sciences Centre; IrlandaFil: Hickey, Rita M.. Teagasc Food Research Centre; IrlandaFil: Rudd, Pauline M.. National Institute for Bioprocessing, Research and Training. NIBRT GlycoScience Group; Irland

Fluorescently tagged star polymers by living radical polymerisation for mucoadhesion and bioadhesion

The synthesis of 3-, 5- and 8-arm dimethylaminoethyl methacrylate star polymers are reported, final Mn (PDI) = 12.2 K (1.09), 18.9K (1.10) and 38.4 K (1.11), respectively. The synthesis of 3-arm methyl methacrylate and dimethylaminoethyl methacrylate block co-polymer stars is also described. Living polymerisation occurred in all cases providing well defined stars with predictable molecular weights and narrow polydispersity. A fluorescent tag, 2-(8-methacryloyloy-3,6-dioxaoctyl)thioxantheno[2,1,9-dej]isoquinoline-1,3-dione, derived from a commercially available pigment, was incorporated into the star polymers. The fluorescence spectra of the polymers prepared were recorded over a range of pH and the peak emission frequency and intensity have been reported, λex = 462 nm. All of the multi-arm polymers exhibit fluorescence across a broad pH range with maximum emission at pH 4. A 3-arm star polymer has been demonstrated to show good bioadhesion in rat tissue. A reduced adhesion in epithelial tissues not covered by a viscoelastic mucus gel indicates an increased tendency for mucoadhesion over bioadhesion.We thank Clariant for the kind donation of the hostasol precursor and Genzyme for part funding this work. D.M. Haddleton would also like to thank Professor John Ebdon for all of his encouragement and support throughout his academic career

KIR/HLA Pleiotropism: Protection against Both HIV and Opportunistic Infections

The compound genotype KIR3DS1/HLA-B Bw4-80I, which presumably favors natural killer cell activation, has been implicated in protection against HIV disease. We show that this genotype confers dual protection over the course of HIV disease; early direct containment of HIV viral load, and late specific defense against opportunistic infections, but not AIDS-related malignancies. The double protection of KIR3DS1/Bw4-80I in an etiologically complex disease such as AIDS, along with the disease specificity of its effects is conceptually novel and underscores the intricacy of host immunogenetics against HIV/AIDS

CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome.

Multiple genome-wide studies have identified associations between outcome of human immunodeficiency virus (HIV) infection and polymorphisms in and around the gene encoding the HIV co-receptor CCR5, but the functional basis for the strongest of these associations, rs1015164A/G, is unknown. We found that rs1015164 marks variation in an activating transcription factor 1 binding site that controls expression of the antisense long noncoding RNA (lncRNA) CCR5AS. Knockdown or enhancement of CCR5AS expression resulted in a corresponding change in CCR5 expression on CD4+ T cells. CCR5AS interfered with interactions between the RNA-binding protein Raly and the CCR5 3' untranslated region, protecting CCR5 messenger RNA from Raly-mediated degradation. Reduction in CCR5 expression through inhibition of CCR5AS diminished infection of CD4+ T cells with CCR5-tropic HIV in vitro. These data represent a rare determination of the functional importance of a genome-wide disease association where expression of a lncRNA affects HIV infection and disease progression

Delayed differentiation of vaginal and uterine microbiomes in dairy cows developing postpartum endometritis

Bacterial overgrowth in the uterus is a normal event after parturition. In contrast to the healthy cow, animals unable to control the infection within 21 days after calving develop postpartum endometritis. Studies on the Microbial Ecology of the bovine reproductive tract have focused on either vaginal or uterine microbiomes. This is the first study that compares both microbiomes in the same animals. Terminal Restriction Fragment Length Polymorphism of the 16S rRNA gene showed that despite large differences associated to individuals, a shared community exist in vagina and uterus during the postpartum period. The largest changes associated with development of endometritis were observed at 7 days postpartum, a time when vaginal and uterine microbiomes were most similar. 16S rRNA pyrosequencing of the vaginal microbiome at 7 days postpartum showed at least three different microbiome types that were associated with later development of postpartum endometritis. All three microbiome types featured reduced bacterial diversity. Taken together, the above findings support a scenario where disruption of the compartmentalization of the reproductive tract during parturition results in the dispersal and mixing of the vaginal and uterine microbiomes, which subsequently are subject to differentiation. This differentiation was observed early postpartum in the healthy cow. In contrast, loss of bacterial diversity and dominance of the microbiome by few bacterial taxa were related to a delayed succession at 7DPP in cows that at 21 DPP or later were diagnosed with endometritis.Department of Agriculture, Food and the MarineScience Foundation Irelan

External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias:a network meta-analysis

BackgroundAtrial fibrillation (AF) is the most frequent sustained arrhythmia. Cardioversion is a rhythm control strategy torestore normal/sinus rhythm, and can be achieved through drugs (pharmacological) or a synchronized electricshock (electrical cardioversion).ObjectivesTo assess the efficacy and safety of pharmacological and electrical cardioversion for AF.Search methodsWe searched CENTRAL, MEDLINE, Embase, Conference Proceedings Citation Index-Science (CPCI-S) andthree trials registers (ClinicalTrials.gov, WHO ICTRP and ISRCTN) on 14 February 2023.Selection criteriaWe included randomised controlled trials (RCTs) at individual patient level. Patient populations were aged ≥18years with AF of any type and duration, atrial flutter or other sustained related atrial arrhythmias, not occurring asa result of reversible causes.Data collection and analysisWe used standard Cochrane methodology to collect data and performed a network meta-analysis using thestandard frequentist graph-theoretical approach using the netmeta package in R. We used GRADE to assess thequality of the evidence which we presented in in our summary of findings with a judgement on certainty. Wecalculated differences using risk ratios (RR) and 95% confidence intervals (CI) as well as ranking treatmentsusing a P-score. We assessed clinical and statistical heterogeneity and split the networks for the primaryoutcome and acute procedural success due to concerns about violating the transitivity assumption.Main resultsWe included 112 RCTs (139 records), from which we pooled data from 15,968 patients. Average age was 47 to72 years and proportion of male patients was 38%-92%.79 trials were considered high risk of bias for at least one domain, 32 had no high risk of bias domains, but hadat least one domain classified as uncertain risk, and one study was considered low risk for all domains.For paroxysmal AF (35 trials), when compared to Placebo, AA/AP BTE incremental cardioversion (RR: 2.42;95%CI 1.65 to 3.56), quinidine (RR: 2.23; 95%CI 1.49 to 3.34), ibutilide (RR: 2.00; 95%CI 1.28 to 3.12),propafenone (RR: 1.98; 95%CI 1.67 to 2.34), amiodarone (RR: 1.69; 95%CI 1.42 to 2.02), sotalol (RR: 1.58;95%CI 1.08 to 2.31) and procainamide (RR: 1.49; 95%CI 1.13 to 1.97) likely result in a large increase inmaintenance of sinus rhythm until hospital discharge or end of study follow-up (certainty of evidence: moderate).The effect size was larger for AA/AP incremental and was progressively smaller for the subsequent interventions.Despite low certainty of evidence Antazoline may result in a large increase (RR: 28.60; 95%CI 1.77 to 461.30) inthis outcome. Similarly, low certainty evidence suggests a large increase on this outcome for flecainide (RR: 2.17;95%CI 1.68 to 2.79), vernakalant (RR: 2.13; 95%CI 1.52 to 2.99), and magnesium (RR: 1.73; 95%CI 0.79 to 3.79)on this outcome.For persistent AF (26 trials), one network was created for electrical cardioversion and showed that whencompared to AP BTE incremental energy with patches, AP BTE maximum energy with patches (RR 1.35, 95%CI1.17 to 1.55) likely results in large increase and Active compression AP BTE incremental energy with patches(RR: 1.14, 95%CI 1.00 to 1.131) likely results in an increase in maintenance of sinus rhythm at hospital dischargeor end of study follow-up (certainty of evidence: high). Use of AP BTE incremental with paddles (RR: 1.03, 95%CI0.98 to 1.09; certainty of evidence: low) may lead to a little increase, and AP MDS Incremental paddles (RR: 0.95,95%CI 0.86 to 1.05; certainty of evidence: low) may lead to a little decrease in efficacy. On the other hand, APMDS incremental energy using patches (RR: 0.78, 95%CI 0.70 to 0.87), AA RBW incremental energy withpatches (RR: 0.76, 95%CI 0.66 to 0.88), AP RBW incremental energy with patches (RR: 0.76, 95%CI 0.68 to0.86), AA MDS incremental energy with patches (RR: 0.76, 95%CI 0.67 to 0.86) and AA MDS incremental energywith paddles (RR: 0.68, 95%CI 0.53 to 0.83) probably result in a decrease on this outcome when compared to APBTE incremental energy with patches (certainty of evidence: moderate). The network for pharmacologicalcardioversion showed that Bepridil (RR: 2.29, 95%CI 1.26 to 4.17) and Quindine (RR: 1.53, (95%CI 1.01 to 2.32)probably result in large increase in maintenance of sinus rhythm at hospital discharge or end of study follow-upwhen compared to amiodarone (certainty of evidence: moderate). Dofetilide (RR: 0.79, 95%CI 0.56 to 1.44),Sotalol (RR: 0.89, 95%CI 0.67 to 1.18), Propafenone (RR: 0.79, 95%CI 0.50 to 1.25) and Pilsicainide (RR: 0.39,95%CI 0.02 to 7.01) may result in a reduction of this outcome when compared to amiodarone, but certainty ofevidence is lowFor atrial flutter (14 trials) a network could be created only for antiarrhythmic drugs. Using Placebo as thecommon comparator, ibutilide (RR: 21.45, 95%CI 4.41 to 104.37), propafenone (RR: 7.15, 95%CI 1.27 to 40.10),dofetilide (RR: 6.43, 95%CI 1.38 to 29.91), and sotalol (RR: 6.39, 95%CI 1.03 to 39.78) probably result in a largeincrease in maintenance of sinus rhythm at hospital discharge or end of study follow-up (certainty of evidence:moderate), and procainamide (RR: 4.29, 95%CI 0.63 to 29.03), flecainide (RR 3.57, 95%CI 0.24 to 52.30) andvernakalant (RR: 1.18, 95%CI 0.05 to 27.37) may result in a large increase of maintenance of sinus rhythm athospital discharge or end of study follow-up at (certainty of evidence: low) All tested electrical cardioversionstrategies for atrial flutter had very high efficacy (97.9% to 100%).Mortality (14 deaths) and Stroke or systemic embolism (3 events) at 30 days was extremely low.Data on quality of life were scarce and of uncertain clinical significance. No information was available regardingheart failure readmissions. Data on duration of hospitalization was scarce, low quality, & could not be pooled.Authors' conclusionsDespite the low quality of evidence, this systematic review provides important information on electrical andpharmacological strategies to help patients and physicians deal with AF and atrial flutter.Assessing the patient comorbidity profile, antiarrhythmic drug onset of action & side effect profile vs. need for aphysician with experience in sedation, or anaesthetics support, for electrical cardioversion are key aspects whenchoosing the cardioversion method

Corrections to the Electroweak Effective Action at Finite Temperature

We calculate contributions to the finite temperature effective action for the electroweak phase transition (EWPT) at \O(g^4), {\it i.e.} at second order in (g^2 T/\M) and all orders in (g^2 T^2/\M^2). This requires plasma-mass corrections in the calculation of the effective potential, inclusion of the ``lollipop'' diagram, and an estimate of derivative corrections. We find the EWPT remains too weakly first-order to drive baryogenesis. We calculate some one loop kinetic energy corrections using both functional and diagrammatic methods; these may be important for saddlepoint configurations such as the bounce or sphaleron.Comment: LaTeX, 6 figures available by email, CALT-68-1795, HUTP-92-A027, EFI-92-2

Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1

Allotypes of the natural killer (NK) cell receptor KIR3DL1 vary in both NK cell expression patterns and inhibitory capacity upon binding to their ligands, HLA-B Bw4 molecules, present on target cells. Using a sample size of over 1,500 human immunodeficiency virus (HIV)+ individuals, we show that various distinct allelic combinations of the KIR3DL1 and HLA-B loci significantly and strongly influence both AIDS progression and plasma HIV RNA abundance in a consistent manner. These genetic data correlate very well with previously defined functional differences that distinguish KIR3DL1 allotypes. The various epistatic effects observed here for common, distinct KIR3DL1 and HLA-B Bw4 combinations are unprecedented with regard to any pair of genetic loci in human disease, and indicate that NK cells may have a critical role in the natural history of HIV infection